Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Positive opinions based on significant survival benefit
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Subscribe To Our Newsletter & Stay Updated
